key: cord-0757573-4snfwx8r
authors: Razonable, Raymund R.; Pennington, Kelly M.; Meehan, Anne M.; Wilson, John W.; Froemming, Adam T.; Bennett, Courtney E.; Marshall, Ariela L.; Virk, Abinash; Carmona, Eva M.
title: A Collaborative Multidisciplinary Approach to the Management of Coronavirus Disease-19 in the Hospital Setting
date: 2020-05-30
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2020.05.010
sha: 8bc13ca1391fff95ac3298b0caf75ad6708b2c8f
doc_id: 757573
cord_uid: 4snfwx8r

• Supportive care is the standard approach to the management of coronavirus disease-19, with particular attention to respiratory support, and early detection of potential complications such as cytokine storm and organ dysfunction. • Therapeutic management of coronavirus disease-19 using antivirals and immunomodulators remain investigational, and should be implemented using clinical trial protocols. • 3. A multidisciplinary collaborative approach to management of coronavirus disease-19 is an essential component of providing optimal care to patients.

Coronavirus disease 2019 (COVID-19) is a new acute respiratory illness caused by a novel zoonotic pathogen, the Severe Acute Respiratory Syndrome-coronavirus 2 (SARS-CoV-2). [1] [2] [3] [4] [5] Since the first cases were reported in December 2019 from Wuhan in China, 1 the infection has rapidly spread worldwide. 6 Declared by the World Health Organization as a global pandemic on March 11, 2020 , COVID-19 has altered societal norms and human behavior in very profound ways, as communities attempt to "flatten the curve." 7, 8 This public health strategy is an effort to minimize the impact on the healthcare system of a "surge" of cases that require hospitalization. 7 Supportive care is the standard approach to management of COVID-19. Since there is no proven effective antiviral treatment or vaccine, medical providers are scrambling to learn about this disease in order to provide best management. Herein, a collaborative team of physicians reviewed the rapidly-evolving literature (published on PubMed, Medline and journal and society websites) on COVID-19 in their respective specialties. In the process, we provide a concise practical review that summarizes the clinical management of COVID-19 in the hospital setting, including the evaluation of patients, diagnostic testing, treatment strategies and infection prevention measures.

SARS-CoV-2 belongs to a family of large enveloped RNA viruses with a "crown" (corona) like appearance. 9, 10 Until 2019, there were six coronaviruses that cause human disease. Four of these, human coronavirus NL63, 229E, OC43 and HKU1 cause seasonal outbreaks of respiratory infections. 11 The other two, Severe Acute Respiratory Syndrome-coronavirus (SARS-CoV) and

Middle East Respiratory Virus Syndrome-coronavirus (MERS-CoV), have caused pandemics in patient with unusual pneumonia in January 2020. 1, 13 Phylogenetic analysis shows 96% homology to a bat corona-like virus and 79% similarity to SARS-CoV. 1,13 Its Spike protein binds to the Angiotensin Converting Enzyme 2 (ACE-2) receptor that is expressed on respiratory epithelium, type II pneumocytes, and epithelial cells of various organs including the gastrointestinal tract and kidneys. [14] [15] [16] [17] The reproductive number (R0) of SARS-CoV-2 is 2-4, which means that every infected person can potentially transmit the virus to 2-4 susceptible individuals. 18, 19 While initial cases were linked to a live animal and seafood market in Wuhan, person to person transmission in the community was quickly documented. 20 The virus is transmitted between humans by respiratory droplets, aerosols and fomites. 21 22 The isolation of SARS-CoV-2 in stool suggests that it may be transmitted by fecal oral route, although this has not yet been proven. 23 Initial Evaluation COVID-19 should be suspected in any patient with fever, respiratory or other symptoms (Table) . Most patients with suspected COVID-19 can be initially evaluated using phone or electronic visits in order to reduce the potential for viral transmission in the hospital or clinic (see telemedicine Initial evaluation should define disease severity. 36, 52 Laboratory and radiographic evaluation are generally not required for patients with mild COVID- 19. 37 In patients who require hospitalization for moderate to severe and critical pneumonia, 5 the initial laboratory evaluation includes complete blood count with differential, inflammatory markers (e.g., C-reactive protein) and metabolic profile including assays of renal and liver status (Figure 1) . D-dimer, fibrinogen, soluble fibrin monomer complex level, and prothrombin time should be assessed to evaluate coagulopathy. 52-55 These initial tests are needed to stratify the risk of disease progression, and guide supportive measures to prevent complications. Procalcitonin, interleukin-6 (IL-6), ferritin, BNP, troponins, and G6PD are potentially helpful,, when clinically indicated, to assess inflammatory status, potential complications, and guide treatment selection. 53 The most common laboratory abnormalities are lymphopenia (63-83%), leukopenia (9-34%), leukocytosis (6-30%), and thrombocytopenia (36%). 2,3,5,53 A high neutrophil to lymphocyte ratio and eosinopenia are indicators of severe disease. Erythrocyte sedimentation rate, CRP, D-dimer, ferritin, and IL-6 are typically elevated, 2,3,5,53 while procalcitonin is normal. 56 When respiratory co-infection is suspected, patients may be tested for other pathogens, particularly influenza. 57, 58 A portable CXR is suggested in patients with at least moderate respiratory symptoms in order to assess the severity of pneumonia and identify concomitant processes (Figure 2 ). Electrocardiogram may also be considered, especially if utilizing drug therapies that cause QTc-prolongation or if there is concern for acute coronary syndrome (ACS) or myocarditis. 

The diagnosis of COVID-19 requires laboratory confirmation of the presence of SARS-CoV-2 by polymerase chain reaction (PCR) of clinical specimens. 49, 59 CDC recommends that healthcare providers work with local health departments to refer patients for testing using an GGOs are commonly described to have rounded or nodular morphology. Progression of COVID-19 is characterized by increasing extent and density of opacities, consolidation and "crazypaving" appearance, and organization with fibrosis.

Many CT findings are not commonly seen with COVID-19, and indicate alternate or additional disease processes. These include upper lobe or perihilar distribution, "tree-in-bud" centrilobular nodularity, pleural effusions, cavitation, discrete solid nodules, and lymphadenopathy.

In 5-10% of patients, COVID-19 progresses to severe and critical hyper-inflammatory stage that is associated with end-organ damage, most commonly with lung injury and acute respiratory distress syndrome (ARDS). Patients are usually admitted to the intensive care unit (ICU) where they receive respiratory and hemodynamic support. 39, 72 Severe lymphopenia is a common risk factor for severe COVID-19, 39 with reduction in helper, suppressor and regulatory T cells. 53, 73, 74 Studies demonstrate elevated IL-6, CRP and ferritin in patients with severe COVID-19, suggesting a pro-inflammatory process. 28, 52, 53 Elevated levels of IL-2R, IL-7, IL-10, TNF-α, granulocyte-colony stimulating factor and macrophage inflammatory protein 1-α are also observed. 75 It is hypothesized that this pro-inflammatory state triggers the critical illness in COVID-19, but whether these cytokines are the cause or consequence of lung injury is not clear.

Mortality among patients with severe and critical COVID-19 is 26%, 72 but is markedly higher in older individuals with significant comorbidity. 39 Clinical trials of immunomodulatory drugs aimed at suppressing the cytokine release syndrome are underway (discussed below).

Respiratory failure is the most common mechanism of death in COVID-19. 2,3,5,28 Its onset is typically during the second week of illness, with a median time of ICU admission of 10-12 days. 75 A subset of patients may progress rapidly to ARDS, with median of 2.5 days from onset of dyspnea. Hypoxemic respiratory failure occurs in 10-20% of patients, while ARDS develops in 3-5%. 2 Early identification of progressive respiratory failure is needed to escalate the level of care and apply important interventions such as high flow oxygen, mechanical ventilation, prone position and other supportive measurements. Classic ARDS is characterized by impaired gas exchange, decreased lung compliance, and increased pulmonary arterial pressure. 76 In contrast, severe hypoxemia with well-preserved lung mechanics and high lung compliance have been described in COVID-19. 77 As previously described in ARDS, 78 microvascular thrombi in the lungs secondary to pulmonary microvascular coagulopathy is seen in COVID- 19. 79 Best practice for mechanical ventilation in ARDS recommends low tidal volumes (4-8 ml/kg predicted bodyweight), low end inspiratory pressures (plateau pressure less than 30 cmH 2 O) and low driving pressure (tidal volume over respiratory system compliance less than 15 cmH 2 O) to prevent ventilator-induced lung injury in the setting of reduced lung compliance. 80 ARDS management such as fluid-restrictive strategies need to be individualized since dehydration and intravascular depletion are frequent in COVID-19. It is important that we understand that the current ARDS guidelines are not tailored to all aspects of COVID-19 induced ARDS and they need to be individualized in the context of patient-specific presentation and other comorbidities. 82 The use of non-invasive positive pressure ventilation or high-flow nasal cannula oxygen with self-proning in COVID-19 ARDS is controversial but may prevent intubation in some patients. 83 The timing of intubation is debated, as it must balance the risk of lung injury with the need for deep-sedation, neuromuscular blockade, and prolonged mechanical ventilation.

The optimal oxygenation goal should be targeted to a SpO 2 between 92 and 96 percent unless there is evidence of other chronic pulmonary conditions that may result in hypercapnic respiratory failure. 82

The cardiovascular complications in COVID-19 can be due to cardiac injury secondary to SARS-CoV-2 infection and the increased risk among patients with cardiovascular diseases. [84] [85] [86] Significant cardiovascular sequelae include myocardial injury (significant rise in serum troponin) with acute cardiac injury and fulminant myocarditis, arrhythmias, and circulatory collapse, 85, 87-89 especially in patients with underlying cardiovascular diseases. 85, 86, 90 Hypertension is the most common comorbidity. 85,90-92 Less common cardiovascular comorbidities include coronary vascular and cerebrovascular disease, and chronic heart failure. 90, 92 Clinical manifestations of myocardial injury in COVID-19 range from mild asymptomatic elevations in cardiac biomarkers to severe fulminant myocarditis and shock. 28, 91, 93 In a study of 138 patients, acute cardiac injury (7.2%), shock (8.7%), and arrhythmia (16.7%) were frequent. 91 In 113 patients that died of COVID-19, the incidence of acute cardiac injury, 23% of 191 hospitalized patients. 95 Acute cardiac injury may manifest as the phenomenon of STsegment elevation without acute coronary artery occlusion, which may represent myocarditis. 88, 96 The mechanism of myocardial injury is likely multifactorial, including demand ischemia, toxic-metabolic effects, cytokine storm, direct viral cardiomyocyte injury, and inflammation triggering coronary plaque rupture. 89,97,98 Cardiac pericytes have high expression of ACE2 receptorst, 99 but there is insufficient data to implicate this pathway. While the pathogenesis of the cardiovascular sequelae is unclear, there is evidence that myocardial injury associated with acute respiratory illnesses is independently associated with mortality. 100 It is important to differentiate ACS from other causes of troponin elevation in the setting of acute illness. 87 Cardiology consultation is recommended when there are findings of myocardial ischemia (i.e., angina, ST-segment changes on ECG, and/or regional wall motion abnormalities on echocardiogram) in the setting of myocardial injury, new or worsening heart failure, and arrhythmias. Treatment of the underlying disease and supportive care is recommended for myocardial injury in the absence of ACS. 101 In patients with ST-segment elevation, a multidisciplinary evaluation should guide the decision for coronary angiography, 102 taking into account the severity of illness and the potential benefit from coronary revascularization. 103 No specific medical therapy is recommended for acute myocarditis, and routine endomyocardial biopsy is discouraged because it is unlikely to change management, and there are associated risks. 104

Mild to moderate elevations in serum aminotransferases and bilirubin are common in hospitalized or critically ill patients with severe COVID-19. 58,105 While liver enzyme abnormalities are more common in severe disease, patients seldom develop acute liver failure or obvious intrahepatic cholestasis. 52,106 Supportive care and avoidance of hepatotoxic drugs in patients with COVID-19 is recommended. Liver damage from virally induced cytotoxic T cells and dysregulation of the innate immune response has been proposed as the mechanism for liver enzyme elevation, rather than viral hepatitis. 107

Elevation of serum creatinine is frequent in COVID-19 and likely due to hypovolemia from poor oral intake, fever, and diarrhea. 108 Elevated serum creatinine and BUN was reported in 15% of patients, while acute kidney injury (AKI) was reported in 1-15% of hospitalized patients, and 20% of critically-ill patients. 39, 108 Proteinuria and hematuria were common. 109 AKI occurs 13-20 days after hospital admission, and associated with in-hospital mortality. 55,109,110 Adequate assessment and monitoring of fluid status is therefore essential in all patients with COVID-19.

Of those who developed AKI, about 1-5% may require renal replacement therapy. 94, 105 Autopsies of six patients with COVID-19 showed severe acute tubular necrosis. 111 Acute tubular necrosis is likely secondary to shock, hypotension, and/or hypovolemia, although direct tubular injury from the virus has been hypothesized. 111, 112 Angiotensin II pathway activation and coagulopathy leading to microvascular thrombosis are also a likely contributor of AKI. 113, 114 Renal abnormalities often resolve within 3 weeks after onset of symptoms. Severity of pneumonia was correlated with lower odds of AKI recovery. 110 Thrombotic complications are common in patients with COVID-19 who are critically ill. 121 Some data supports the hypothesis that inhibiting thrombin generation with anticoagulation in patients with sepsis-associated coagulopathy may be associated with decreased mortality. One small study showed lower mortality rates among patients with COVID-19 and elevated D-dimer who received prophylactic heparin. 79 Another study observed lower mortality in patients with high sepsis-induced coagulopathy scores or extremely elevated D-dimer levels who received prophylactic-dose low-molecular weight heparin (LMWH) or unfractionated heparin. 122 Prophylactic LMWH should be considered in all patients requiring hospitalization for COVID-thrombotic rates of up to 31% have been demonstrated in critically ill patients in ICU (27% venous thromboembolism, 3.7% arterial thrombosis). 121 

Patients with COVID-19 may develop co-infection with other respiratory pathogens. The rate of co-infection ranges from 4-35% of patients depending on the series and the season. 58, 123 In one study, 24 of 116 specimens had SARS-CoV-2 co-infection with rhinovirus, enterovirus, respiratory syncytial virus, and other coronaviruses. In another study, the most commonly reported co-infection is influenza. 58 Early detection of co-existing influenza infection is critical for the prompt initiation of appropriate influenza-specific therapy. Currently, there is limited data on bacterial or fungal co-infection, but suspicion for this possibility must remain high, especially among COVID-19 patients on extended mechanical ventilation. Once bacterial superinfection is suspected, empiric antibiotics may be initiated while microbiologic work-up is undertaken.

Suspicion for superimposed co-infection may be suggested by "indeterminate" or "atypical" radiographic features.

Person-to-person spread of SARS-CoV-2 occurs mainly by respiratory droplets and 

The standard of care for COVID-19 is supportive management including analgesics, fluids, electrolytes and oxygen supplementation. 124 . There is no solid evidence to suggest that NSAIDs worsen COVID-19 symptoms. 124, 125 

Pharmaceutical management of COVID-19 takes into account the stage of illness. During the early stage (e.g., during the first week) when the pathology is driven mainly by viral replication, an effective antiviral therapy is desired. The goal of management is to suppress viral replication in order to prevent systemic or end-organ disease. However, there is no drug proven to be clinically effective. 124 Thus, participation in controlled clinical trials of experimental and repurposed drugs is recommended. 124, 125 Remdesivir, an RNA-dependent RNA polymerase inhibitor, was shown to have 127 modest efficacy in a cohort of 53 patients who participated in a compassionate-use program. 127 A placebo-controlled trial (which was prematurely stopped because of poor enrollment since the pandemic was slowing down in China) showed that remdesevir was not associated with significant clinical improvement. 128 However, the (unpublished) clinical trial sponsored by the National Institutes of Health demonstrated that remdesivir was significantly associated with faster time to clinical improvement. 129 The US FDA has granted emergency use authorization for remdesivir for the treatment of COVID- 19. 130 Favipiravir is another viral RNA polymerase inhibitor undergoing controlled clinical trials. 124 The anti-HIV protease inhibitor lopinavir-ritonavir, the antimalarial chloroquine and anti-inflammatory hydroxychloroquine are being re-purposed and evaluated for their efficacy in COVID-19. 126, 131, 132 The randomized controlled trial that evaluated lopinavir-ritonavir in patients with severe COVID-19 did not show significant clinical benefit when compared to supportive care. 126 Convalescent plasma has been suggested for the treatment of COVID-19. It is hypothesized that antibody to SARS-CoV-2 in plasma of persons who have recovered from the illness may be efficacious in controlling viral infection. The FDA has authorized an expanded access program on the use of convalescent plasma for treatment of COVID-19. Initial experience of 5 patients with COVID-19 pneumonia reported fever resolution, improvement in sequential organ failure assessment scores, decline in viral load, and resolution of ARDS. 133 The outcome of the ongoing registry of thousands of patients who received convalescent plasma using the expanded access program in the US is eagerly awaited.

For the 5% of patients that progress to develop severe systemic hyper-inflammatory syndrome, the goal of treatment is to control the pro-inflammatory state. In this regard, immunomodulators such as IL-6 inhibitors (sarilumab, tocilizumab, others), GM-CSF inhibitors (lenzilumab), IL-1 receptor antagonist (anakinra), among others, are proposed. 124 Several clinical trials are underway to assess the safety and efficacy of these immunomodulators for treatment of severe, critical and life-threatening COVID-19. 125 Safe criteria for hospital dismissal include having been afebrile and stable hemodynamically for at least 48 hours, a stable and safe respiratory status whether or not requiring oxygen, able to conduct activities of daily living, alert cognition, having a place to be safely dismissed to, the ability to self-isolate at home to protect other family members, and presence of a home provider who can continue the care for these patients (Table) Patients who were residents of congregate settings such as skilled nursing facilities prior to hospitalization pose additional dismissal challenges. These patients can return to their place of residence if the facility has the ability to isolate and care for the patient. If that is not feasible, many of these patients may not be discharged from the hospital until they have recovered from the illness and tested negative for the SAR-CoV2 by nasopharyngeal PCR. 135, 136 Telemedicine During this pandemic of a highly infectious virus, the need to limit patients' movements and to manage them remotely is desired. Telemedicine is essential to monitor the patients clinical status remotely to identify early clinical warning signs and to decrease potential exposure to others including healthcare workers. Telemedicine in this context not only includes phone calls and video visits but also remote monitoring of symptoms and vital signs such as temperature, heart and respiratory rate, blood pressure, and oxygen saturations from home via devices or smartphones apps. 47, 48 In March 2020, the FDA allowed manufacturers of certain non-invasive, vital sign-measuring devices to expand their use so that healthcare providers can use them to monitor patients remotely. Additionally, during this pandemic, privacy and data protection regulations for video and remote communications with patients have been relaxed to allow quicker and easier access of patients to their healthcare team. These in-home monitoring devices can collect data intermittently or continuously and can be programed to gather more or less intensive data, depending on the patients' risk category. Some of these patients may require remote cardiac rhythm monitoring such as Life vest or body guardian especially if they developed new arrhythmia or new heart failure with low ejection fraction (<35%) during hospitalization. These remote monitoring tools allow the clinical team to identify abnormal biometrics early to rapidly triage and escalate care with either in-home management or transfer to an emergency department or an infusion center for management. Remote monitoring devices and clinical teams also serve to re-inforce to the patient to remain in home isolation and, at the end of their illness, assist in releasing the patient from isolation precautions. 135, 136 Conclusions COVID-19 presents a significant challenge to medical providers worldwide. Management of the disease is mostly supportive care with antipyretics, hydration and oxygen supplementation, as dictated by clinical need. For patients with moderate-to-severe COVID-19 that requires hospitalization, medical complications affecting various organ systems are not uncommon, and may lead to critical illness and multi-organ failure. Hence, the medical care of patients with COVID-19 is best optimized by the collaboration among various healthcare providers from different specialties. As illustrated in this management review, clinical expertise in hospital medicine, infectious diseases, clinical microbiology, radiology, pulmonary and critical care medicine, cardiology, hematology and primary care are essential in ensuring that medical complications are prevented or treated early and aggressively. Finally, when patients are medically ready for hospital dismissal, telemedicine will provide proper follow up and monitoring until the patients have medically recovered from their illness and ready to be released from home quarantine protocols.

van An elderly man with history of congestive heart failure, atrial fibrillation and hypertension presented to the Emergency Department for progressive dyspnea over a course of 3 weeks. Portable CXR shows patchy peripheral opacities bilaterally (A). Chest CT angiogram was negative for pulmonary embolism or signs of heart failure, but had typical findings commonly reported for coronavirus disease-19. Axial and coronal CT images in lung windows show patchy bilateral ground-glass opacities with a peripheral and lower lung distribution (B, C).

A new coronavirus associated with human respiratory disease in China

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Clinical Characteristics of Coronavirus Disease 2019 in China

Early Introduction of Severe Acute Respiratory Syndrome Coronavirus 2 into Europe

Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan

US Public Concerns About the COVID-19

Pandemic From Results of a Survey Given via Social Media

A Novel Coronavirus Emerging in China -Key Questions for Impact Assessment

SARS and MERS: recent insights into emerging coronaviruses

Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method

Origin and evolution of pathogenic coronaviruses

A Novel Coronavirus from Patients with Pneumonia in China

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Structure analysis of the receptor binding of 2019-nCoV

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Early phylogenetic estimate of the effective reproduction number of SARS-CoV-2

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin

Role of acute infection in triggering acute coronary syndromes

Potential Effects of Coronaviruses on the Cardiovascular System: A Review

The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2

Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review

Type 2 Myocardial Infarction: JACC Review Topic of the Week

Considerations for cardiac catheterization laboratory procedures during the COVID-19 pandemic perspectives from the Society for Cardiovascular Angiography and Interventions Emerging Leader Mentorship (SCAI ELM) Members and Graduates

ST-segment Elevation, Myocardial Injury, and Suspected or Confirmed COVID-19 Patients: Diagnostic and Treatment Uncertainties

Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease

COVID-19 and the liver: little cause for concern

Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China

Kidney disease is associated with in-hospital death of patients with COVID-19

Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia

The novel coronavirus (COVID-19) infection in Hangzhou: An experience to share

Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

Prominent changes in blood coagulation of patients with SARS-CoV-2 infection

Tissue Plasminogen Activator (tPA) Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Case Series

Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens

Treatment considerations for COVID-19: A critical review of the evidence (or lack thereof)

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-192020

COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID

Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

31%) Less Common: • Sore throat, sputum, hemoptysis, rhinorrhea • Headache, anosmia, dysgeusia • Nausea, vomiting , diarrhea

• Lymphopenia (63%) • Leukocytosis (24-30%) • Leukopenia (9-25%) LFTs: 

• Quarantine for 7 days from hospital discharge or 14 days total since onset of disease (whichever is longer) • At least 72 hours have passed since resolution of fever without the use of antipyretics • Improvement in respiratory symptoms • COVID-19 PCR testing at day 7 of discharge being negative